

Aaron T Wecksler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5291363/publications.pdf>

Version: 2024-02-01

26
papers

1,030
citations

471509

17
h-index

552781

26
g-index

26
all docs

26
docs citations

26
times ranked

1576
citing authors

#	ARTICLE	IF	CITATIONS
1	Epitope mapping of anti-drug antibodies to a clinical candidate bispecific antibody. <i>MABs</i> , 2022, 14, 2028337.	5.2	8
2	Development of Software Workflow for the Rapid Detection of Cross-Linked Dipeptides. <i>Journal of the American Society for Mass Spectrometry</i> , 2022, 33, 598-602.	2.8	1
3	Antibody-receptor interactions mediate antibody-dependent cellular cytotoxicity. <i>Journal of Biological Chemistry</i> , 2021, 297, 100826.	3.4	19
4	Antigen physicochemical properties allosterically effect the IgG Fc-region and Fc neonatal receptor affinity. <i>MABs</i> , 2020, 12, 1802135.	5.2	18
5	Optimizing Hydroxyl Radical Footprinting Analysis of Biotherapeutics Using Internal Standard Dosimetry. <i>Journal of the American Society for Mass Spectrometry</i> , 2020, 31, 1563-1571.	2.8	8
6	Current Trends in Biotherapeutic Higher Order Structure Characterization by Irreversible Covalent Footprinting Mass Spectrometry. <i>Protein and Peptide Letters</i> , 2019, 26, 35-43.	0.9	5
7	Characterization of ELISA Antibody-Antigen Interaction using Footprinting-Mass Spectrometry and Negative Staining Transmission Electron Microscopy. <i>Journal of the American Society for Mass Spectrometry</i> , 2018, 29, 961-971.	2.8	27
8	Structural basis for dual-mode inhibition of the ABC transporter MsbA. <i>Nature</i> , 2018, 557, 196-201.	27.8	125
9	Photodisruption of the Structurally Conserved Cys-Cys-Trp Triads Leads to Reduction-Resistant Scrambled Intrachain Disulfides in an IgG1 Monoclonal Antibody. <i>Molecular Pharmaceutics</i> , 2018, 15, 1598-1606.	4.6	17
10	Monoclonal antibody targeting the Î²-barrel assembly machine of <i>Escherichia coli</i> is bactericidal. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 3692-3697.	7.1	149
11	Mapping the Binding Interface of VEGF and a Monoclonal Antibody Fab-1 Fragment with Fast Photochemical Oxidation of Proteins (FPOP) and Mass Spectrometry. <i>Journal of the American Society for Mass Spectrometry</i> , 2017, 28, 850-858.	2.8	51
12	Native MS and ECD Characterization of a Fab-Antigen Complex May Facilitate Crystallization for X-ray Diffraction. <i>Journal of the American Society for Mass Spectrometry</i> , 2016, 27, 1139-1142.	2.8	22
13	Inhibition of mutant KrasG12D -initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t-CUPM. <i>Cancer Letters</i> , 2016, 371, 187-193.	7.2	12
14	Effect of ambient light on IgG1 monoclonal antibodies during drug product processing and development. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2016, 100, 38-46.	4.3	65
15	Mapping of Fab-1:VEGF Interface Using Carboxyl Group Footprinting Mass Spectrometry. <i>Journal of the American Society for Mass Spectrometry</i> , 2015, 26, 2077-2080.	2.8	24
16	Characterizing monoclonal antibody structure by carboxyl group footprinting. <i>MABs</i> , 2015, 7, 540-552.	5.2	37
17	Biological evaluation of a novel sorafenib analogue, t-CUPM. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 161-171.	2.3	14
18	Characterizing monoclonal antibody structure by carbodiimide/GEE footprinting. <i>MABs</i> , 2014, 6, 1486-1499.	5.2	7

#	ARTICLE	IF	CITATIONS
19	Novel sorafenib-based structural analogues. <i>Anti-Cancer Drugs</i> , 2014, 25, 433-446.	1.4	3
20	Effect of soluble epoxide hydrolase polymorphism on substrate and inhibitor selectivity and dimer formation. <i>Journal of Lipid Research</i> , 2014, 55, 1131-1138.	4.2	34
21	Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 3732-3737.	2.2	87
22	A novel p21 attenuator which is structurally related to sorafenib. <i>Cancer Biology and Therapy</i> , 2013, 14, 278-285.	3.4	44
23	Synthesis and Structure-Activity Relationship Studies of Urea-Containing Pyrazoles as Dual Inhibitors of Cyclooxygenase-2 and Soluble Epoxide Hydrolase. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 3037-3050.	6.4	148
24	Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy. <i>Cancer Biology and Therapy</i> , 2011, 12, 827-836.	3.4	57
25	Substrate specificity effects of lipoxygenase products and inhibitors on soybean lipoxygenase-1. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 6534-6539.	3.0	21
26	Kinetic and Spectroscopic Studies of N694C Lipoxygenase: A Probe of the Substrate Activation Mechanism of a Nonheme Ferric Enzyme. <i>Journal of the American Chemical Society</i> , 2007, 129, 7531-7537.	13.7	27